ABT 436

Drug Profile

ABT 436

Alternative Names: ABT-436

Latest Information Update: 10 Sep 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Abbott Laboratories
  • Developer Abbott Laboratories; AbbVie; National Institute on Alcohol Abuse and Alcoholism
  • Class Antidepressants; Anxiolytics
  • Mechanism of Action Vasopressin 1b receptor antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes

Highest Development Phases

  • Discontinued Alcoholism; Anxiety disorders; Major depressive disorder

Most Recent Events

  • 01 Mar 2015 AbbVie completes a phase II trial in Alcoholism in USA (NCT01613014)
  • 04 Oct 2013 AbbVie terminates phase II trial in Major depressive disorder in the US (NCT01741142)
  • 03 Jun 2013 AbbVie suspends a phase II trial in Major depressive disorder in USA (NCT01741142)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top